niacinamide has been researched along with Acute Lymphoid Leukemia in 7 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In conclusion, sorafenib is active and well tolerated in acute myelogenous leukemia with fms-like tyrosine kinase 3 internal tandem duplication mutation." | 5.15 | Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. ( Andreeff, M; Borthakur, G; Cortes, JE; Faderl, S; Kantarjian, H; Konopleva, M; Mathews, S; Ravandi, F; Verstovsek, S; Wright, JJ; Zhang, W, 2011) |
| "Distinct clinicopathologic acute lymphoblastic leukemia (ALL) entities have been identified, resulting in the adoption of risk-oriented treatment approaches." | 2.44 | [Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors]. ( Thomas, X, 2007) |
| "We report the results of a phase I dose escalation trial of the multikinase inhibitor sorafenib in relapsed and refractory acute leukemia patients using an intermittent dosing regimen." | 1.36 | A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. ( Baker, SD; Carducci, MA; Cho, E; Gore, SD; Karp, JE; Levis, MJ; McDevitt, M; Pratz, KW; Rudek, MA; Smith, BD; Stine, A; Wright, JJ; Zhao, M, 2010) |
| "Sorafenib displays significant antileukemic activity in vitro by inducing cell cycle arrest and apoptosis." | 1.36 | The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells. ( Amoroso, F; Boldt, S; Dahlhaus, M; Etro, D; Freund, M; Fuellen, G; Glass, A; Junghanss, C; Lange, S; Neri, LM; Ruck, S; Sawitzky, M; Schult, C; Wolkenhauer, O, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Zerbit, J | 1 |
| Tamburini, J | 1 |
| Goldwirt, L | 1 |
| Decroocq, J | 1 |
| Cayuela, JM | 1 |
| Chapuis, N | 1 |
| Contejean, A | 1 |
| Batista, R | 1 |
| Bouscary, D | 1 |
| Willems, L | 1 |
| Perova, T | 1 |
| Grandal, I | 1 |
| Nutter, LM | 1 |
| Papp, E | 1 |
| Matei, IR | 1 |
| Beyene, J | 1 |
| Kowalski, PE | 1 |
| Hitzler, JK | 1 |
| Minden, MD | 1 |
| Guidos, CJ | 1 |
| Danska, JS | 1 |
| Kurosu, T | 1 |
| Ohki, M | 1 |
| Wu, N | 1 |
| Kagechika, H | 1 |
| Miura, O | 1 |
| Pratz, KW | 1 |
| Cho, E | 1 |
| Levis, MJ | 1 |
| Karp, JE | 1 |
| Gore, SD | 1 |
| McDevitt, M | 1 |
| Stine, A | 1 |
| Zhao, M | 1 |
| Baker, SD | 1 |
| Carducci, MA | 1 |
| Wright, JJ | 2 |
| Rudek, MA | 1 |
| Smith, BD | 1 |
| Schult, C | 1 |
| Dahlhaus, M | 1 |
| Ruck, S | 1 |
| Sawitzky, M | 1 |
| Amoroso, F | 1 |
| Lange, S | 1 |
| Etro, D | 1 |
| Glass, A | 1 |
| Fuellen, G | 1 |
| Boldt, S | 1 |
| Wolkenhauer, O | 1 |
| Neri, LM | 1 |
| Freund, M | 1 |
| Junghanss, C | 1 |
| Borthakur, G | 1 |
| Kantarjian, H | 1 |
| Ravandi, F | 1 |
| Zhang, W | 1 |
| Konopleva, M | 1 |
| Faderl, S | 1 |
| Verstovsek, S | 1 |
| Mathews, S | 1 |
| Andreeff, M | 1 |
| Cortes, JE | 1 |
| Thomas, X | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of BAY 43-9006 (NSC 724772) in Patients With Acute Leukemias, Myelodysplastic Syndromes and Chronic Myeloid Leukemia in Blast Phase[NCT00217646] | Phase 1 | 36 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for niacinamide and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
[Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzamides; Benzenesulfonates; Dasatinib; Drug R | 2007 |
1 trial available for niacinamide and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Female; Humans; Leukemia, Lymphocytic, Chronic, B | 2011 |
5 other studies available for niacinamide and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Fusion Proteins, bcr-abl; Humans; Imidazoles; Niacinamide; Philadelphia Chromosome; Precursor Cell L | 2021 |
Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.
Topics: Administration, Oral; Adult; Aminopyridines; Animals; Cell Proliferation; Cell Survival; Child; Fema | 2014 |
Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Topics: Acetophenones; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Benzenesulfona | 2009 |
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Extracellular Signal-Regul | 2010 |
The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells.
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Benzenesulfonates; Caspase 3; Caspase 7; Cell Line, | 2010 |